Skip to main content
. 2022 Jan 15;2022:5528845. doi: 10.1155/2022/5528845

Table 2.

The degree centrality (DC), betweenness centrality (BC), and closeness centrality (CC) values of the key targets for TTNC in treating migraine.

No. Gene name Target name CC DC BC
1 AKT1 AKT serine/threonine kinase 1 0.4345 24 0.1875
2 ESR1 Estrogen receptor 1 0.3544 20 0.0592
3 ESR2 Estrogen receptor 2 0.3427 18 0.0394
4 AR Androgen receptor 0.3318 18 0.0887
5 DNMT1 DNA methyltransferase 1 0.3862 18 0.1141
6 HRAS HRas proto-oncogene, GTPase 0.3596 11 0.0450
7 CYP19A1 Cytochrome P450 family 19 subfamily a member 1 0.2967 10 0.0123
8 NOS1 Nitric oxide synthase, brain 0.3782 10 0.0583
9 HTR1F 5-Hydroxytryptamine receptor 1F 0.2908 9 0.0112
10 HTR2A 5-Hydroxytryptamine receptor 2A 0.2920 9 0.0192
11 PIK3CA Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 0.3510 9 0.0241
12 PTGS2 Prostaglandin G/H synthase 2 0.3349 9 0.0471
13 CREB1 Cyclic AMP-responsive element-binding protein 1 0.3460 8 0.0187
14 HTR1A 5-Hydroxytryptamine receptor 1A 0.3042 8 0.0220
15 INS Insulin 0.2920 7 0.0089
16 SRC Proto-oncogene tyrosine-protein kinase Src 0.3333 7 0.0160
17 DRD2 D(2) dopamine receptor 0.3364 6 0.0205
18 EDNRA Endothelin-1 receptor 0.3160 6 0.0127
19 IGF1R Insulin-like growth factor 1 receptor 0.3318 6 0.0117
20 INSR Insulin receptor 0.3333 6 0.0105